Earnings results for biotech stocks for the first three quarters have been released, with six companies generating profits exceeding one paid-in share capital, outperforming the same period last year. Bora Pharmaceuticals continued to top the list with earnings per share (EPS) of NT$21.34, followed by PEGAVISION at NT$15.38 and Lotus Pharmaceutical at NT$13.82. The top-10 EPS rankings for biotech stocks underwent a major reshuffle in the first three quarters, with PharmaEssentia, UNIVERSAL VISION BIOTECHNOLOGY, and SYNGEN BIOTECH entering the list, while Gin Hwa Biotech, Shinybrands, and DR. WU dropped out.
Notably, amid the impacts of tariffs, exchange rates, and a weaker economic environment, the operating performance of biotech stocks in the first three quarters fell short of expectations. Nevertheless, among the top 30 companies by EPS, ten companies—including Sunmax, Visco Vision, PharmaEssentia, Vizionfocus, Medical Imaging, TTY Biopharm, United BioPharma, Crystalvue, A Plus Biotechnology, and Standard Chemical & Pharmaceutical—still set new highs compared with the same period last year.
Based on preliminary statistics, high-profit biotech stocks in the first three quarters continued to be led by the pharmaceutical, ophthalmology, and beauty and healthcare product segments. Bora Pharmaceuticals, PEGAVISION, Lotus Pharmaceutical, TaiDoc, Sunmax, and Visco Vision all earned more than one paid-in share capital. Companies including PharmaEssentia, Vizionfocus, UNIVERSAL VISION BIOTECHNOLOGY, SYNGEN BIOTECH, Gin Hwa Biotech, Hi-Clearance, TCI, DR. WU, Medical Imaging, Shinybrands, BIOTEQUE, FORMOSA OPTICAL TECHNOLOGY, CHLITINA HOLDING LIMITED, Grape King Bio, and TTY Biopharm also posted EPS starting from NT$5 or higher. United BioPharma, Crystalvue, CH BIOTECH R&D, MIKOBEAUTE, PACIFIC HOSPITAL SUPPLY, A Plus Biotechnology, Standard Chemical & Pharmaceutical, SYN-TECH CHEM. & PHARM., and Excelsior Medical likewise advanced into the top tier of profitability.
Among corporate groups, the Standard Chemical & Pharmaceutical Group continued to deliver the strongest performance. In addition to Standard Chemical & Pharmaceutical reaching a new high, SYNGEN BIOTECH and SYN-TECH CHEM. & PHARM. both ranked among the top 30, with SYNGEN BIOTECH further breaking into the top 10.
Although Bora Pharmaceuticals faced headwinds this year, Chairman Bobby Sheng stated at an investor conference on the 14th that capacity expansion and technological upgrades brought by acquisitions have begun to bear fruit, resulting in a more robust operating structure than last year. The company’s current order backlog has climbed to US$290 million, a historical high, providing visibility of approximately one to one and a half years. Adjustments at the USL facility in the United States are expected to be completed in the first quarter of next year. Going forward, global sales will focus on specialty pharmaceuticals, advanced aseptic manufacturing processes, specialized syringe technologies, and high-end oral dosage forms such as liquid-filled hard capsules, to strengthen differentiated competitiveness. The company maintains a “cautiously optimistic” outlook for 2026.
Lotus Pharmaceutical reported a sharp increase in revenue in October and expects fourth-quarter revenue to once again challenge historical highs, exceeding NT$50 billion, with gross margin likely to return to around 60%. Full-year EPS is projected to reach NT$19–20. The company will hold an investor conference this week and is expected to release more details regarding the integration of Alvogen. Looking ahead to 2026, revenue is expected to have the opportunity to challenge NT$300 billion, solidifying its position as the largest pharmaceutical company by revenue in Taiwan.
Resource: 生技股前三季獲利出爐 前十強大洗牌 這檔EPS 21.34元續稱王
